Pancreatic Carcinoma Non-resectable
7 clinical trials · Condition
◉ Watch Pancreatic Carcinoma Non-resectable
| Record | Firm | Date |
|---|---|---|
| Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (NCT02405585) | NewLink Genetics Corporation | 2015-04-01 |
| Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer (NCT01872377) | Ottawa Hospital Research Institute | 2013-07-01 |
| Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (NCT01836432) | NewLink Genetics Corporation | 2013-05-01 |
| Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer (NCT01851174) | Western Regional Medical Center | 2013-02-01 |
| Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma (NCT01593475) | National Cancer Center, Korea | 2011-09-05 |
| Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer (NCT00761345) | Fox Chase Cancer Center | 2008-09-01 |
Track Pancreatic Carcinoma Non-resectable automatically
Every clearance here is in the API, with alerts when new ones post.